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Available online 31 October 2017Mg-Ca-TiO2 (MCT) composite scaffolds loadedwith different concentrations of doxycycline (DC)with a network
of interconnected poreswith good compressive strength (5± 0.1MPa)were fabricated via space holdermethod
for the first time. The results showed that MCT-DC scaffolds possess a porosity and pore size in the range of
65–67% and 600–800 μm respectively. The bioactivity results exhibited the apatite formation on the MCT-DC
scaffold surface, indicating that DC did not obstruct the bioactivity of MCT. The MCT-DC scaffolds drug release
profiles show the initial burst and sustained drug release (55–75%) and the release rate could be adjusted via al-
tering the DC concentration. TheMCT loaded with 1 and 5% DC did not indicate cytotoxic behavior against MG63
cells while further DC loading resulted in some toxicity. Antimicrobial properties of MCT-DC scaffolds against
Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli) bacteriawere examined and the results reveal obliv-
ious inhibition zone around each MCT-DC scaffold whereas no obvious inhibition is observed around the MCT
scaffold. Therefore, MCT-DC composite scaffolds with low concentration of DC could be alternative candidates
for infection prevention and bone tissue engineering.
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Porous scaffold has an important role in tissue engineering for bone
reconstruction as it permits the growth of new human tissue and accel-
erates the healing process of the bone. Scaffolds were used for bone re-
pair defects, cell adhesion and proliferation and also they can act as a
platform for drug delivery [1–4]. Especially, metallic scaffolds have
been considered for tissue engineering applications because of their ap-
propriate mechanical properties. A number of metallic implant mate-
rials including titanium alloys, stainless steels, cobalt chromium alloys,
zinc alloys, tantalum, nitinol, iron alloys, and magnesium alloys were
generally used for biomedical applications [1,5,6]. Among these, Mg
and it alloys have attracted considerable attention because their density
is in the range of (1.74–2.0 g/cm3) which is lower compared with the
biomedical Co alloy (4.4–4.5 g/cm3), Ti alloy (4.4–4.5 g/cm3), Zn alloy
(~7.14 g/cm3), and iron alloy (~7.87 g/cm3) and is close to that of the
natural bone (1.8–2.1 g/cm3) [7,8]. Mg alloys fracture toughness is
higher compared with the ceramic biomaterials, whereas their Young
modulus (41–45 GPa) is close to that of the bone which leads to the re-
duction of stress shielding effects [4,7]. Porous polymeric scaffolds most
likely are not provided appropriate mechanical properties for bone re-
placement applications [9]. Chen et al. [10] reported that Mg-based al-
loys as better biodegradable materials for load-bearing applications
due to their higher strength and ductility compared to the polymers.
The above advantages of biodegradableMg-based alloys led researchers
to study porous Mg-based composites owing to their higher compres-
sive strength and fracture toughness for bone replacement applications.
Numerous examinations have pointed out that magnesium ions play an
essential role in bone remodeling and development of musculoskeletal
system [11,12]. Thus, magnesium has been used due to its biocompati-
bility, biodegradability, and bioactivity for biomedical applications. Cur-
rently, porousMg scaffolds have received great attention for bone tissue
engineering applications [1,12,13]. However, several issues should be
addressed prior to consideration of porous Mg scaffolds for tissue engi-
neering, most particularly their low corrosion resistance and high deg-
radation rate which causes a serious and adverse inflammatory
response alongwith cytocompatibility [5,14–16]. Therefore,mechanical
alloying as a promisingmethod has been applied to improve the biolog-
ical corrosion resistance of magnesium [17]. In the present study, Mg-
based composites were reinforced via addition of Ca and TiO2 with the
aim of enhancement of the corrosion resistance of Mg scaffolds to
meet the clinical requirements [17–19]. Calcium is a main element in
human bone and improves bone healing process and its addition to
Mg less than solid solubility limit could improve the corrosion resis-
tance ofMgdue to the cathodic secondary phases [20]. However, further
addition of Ca toMg (beyond the solubility limit) has a deleterious effect
on the corrosion behavior. TiO2 as a biocompatible oxide with
osteoconductive properties is also added to the matrix of the Mg-
based composite with the aim of improving corrosion properties [17,
21,22]. However, Mg-based composites presented poor antibacterial
performance which result in implants associated with infections and
lead to post-operative problems. The infection of bone is an essentially
destructive problem with crucial clinical and economic effects [23,24].
It is explained as an inflammatory process which causes bone devasta-
tion generally attributed to the primary microbial infection, mostly
through S. aureus bacteria [3,23,25]. To solve this problem, scaffolds
were incorporated with antibiotics such as doxycycline (DC) as a glyco-
peptide antibiotic which is active against Gram-positive and Gram-
negative bacteria and is able to inhibit the bacterial protein biosynthesis
[26,27]. The incorporation of antibiotics such as DC [24] into Mg-based
composite scaffold prevents the growth of bacterial cells and infection
of the bone. Even though porousMg-based composite scaffolds with in-
terconnected porosities have a crucial role in growth of cells [1,2], a lim-
ited number of researches have been conducted so far regarding the
fabrication and characterization of Mg-based composite as scaffolds.
For example, porous Mg scaffold was fabricated via infiltrating themolten Mg into a NaCl preform accompanied by a subsequent leaching
process [28]. In another study conducted by Staiger et al. [29] porousMg
scaffold was fabricated via negative salt-pattern molding process in
three stages containing design of porous Mg via computer-aided design
and then producing polymeric 3D template followed by sintering
and infiltrating the molten magnesium. Other methods such as
metal/gas eutectic unidirectional solidification, titanium wires as
space holder, gel casting, polymeric sponge, and powder metallurgy
(PM) methods have been applied to produce different types of po-
rous Mg scaffolds [1,5]. Among these methods, powder metallurgy
is the most common method consisted of a mixing of Mg powders
with removable spacer following pressing them and subsequent
sintering process, which has received great attention [5]. This can
be due to the PM being cost-effective method having more control
on the pore size, pores density and morphology as well as ability of
near net shape production. In this context, Seyedraoufi et al. [15]
synthesis of Mg-Zn scaffold via powder metallurgy (mixing of Mg
and Zn with carbamide) and subsequent two-step heating process
to burn out the carbamide particles (250 °C) and sintering the pow-
der (580 °C). Their result revealed that the synthesis Mg–Zn scaffolds
containing 21–36% porosity exhibited higher mechanical properties
comparable to the cancellous bone. However, fabrication and charac-
terization of porous Mg-Ca-TiO2 (MCT) composite scaffold loaded
with doxycycline with antibacterial properties has not been reported
elsewhere. In the present study, space holder as a cost-effective
method with ease of control on the morphology and size of pores
has been employed to fabricate porous MCT composite scaffold load-
ed with DC to enhance antibacterial activity.2. Materials and methods
Pure magnesium (purity ≥99%, 5–20 μm particle size; Sigma-
Aldrich), and calcium (99.5% purity, particle size b80 μm; Sigma-
Aldrich) powders and titanium (IV) oxide (TiO2, anatase nanopowder,
purity N99.7%, b100 nm particle size) which were supplied by Sigma-
Aldrich, were used as the starting materials. The powder mixtures
(Ca powders, 1 wt%; TiO2 powders, 10 wt% and with the balance Mg
powders) were dried in a vacuum dry oven at 220 °C for 10 h and
were subsequently mixed using a planetary ball mill (Retsch, PM400,
Germany) for 4 h in argon atmosphere. The detail of the ball-milling
condition is summarized in Table 1. The space holder method was sub-
sequently applied to attain MCT scaffolds, throughout which the spher-
ical carbamide (CO(NH2)2; Merck, Germany) as the spacer with the
particle size in the range of 600–800 μm and MCT nanopowder with a
weight ratio of 70:30 were mixed. The powder was eventually pressed
under 200MPa at a crosshead speed rate of 2.0 mm/min in a cylindrical
form with a size of 10 mm (diameter) × 15 mm (thickness) and pre-
heated at 180 °C for 2 h to burn out the spacer particles, and was subse-
quently sintered (HT04/17, Nabertherm, Germany) at 580 °C for 2 h at a
heating rate of 5 °C/min in a furnace under the protection of argon gas.
Doxycycline hyclate (DC; Sigma, St. Louis, MO) solutionswere prepared
by dissolving doxycycline powder (10, 50, and 100mg/mL and labelled
as MCT-1DC, MCT-5DC and MCT-10DC) in distilled water. The loading
process was carried out by applying 5 min vacuum before immersion
of each MCT scaffold in the prepared DC solutions. The scaffolds were
agitated on a roller shaker for 24 h and were then dried overnight by
freeze dryer (FD-10, Pishtaz Engineering Co., Iran) according to the
Ref. [25]. Schematic presentation of this method is shown in
Scheme 1. The faces of scaffold for SEM observationsweremechanically
ground down to 4000 grit SiC abrasive paper, and then, washed with
distilled water and ultrasonically degreased in ethanol, and finally,
etched in etched in the solution of 1 vol% HNO3, 75 vol% ethylene glycol
and 25 vol% H2O. The interconnected and true porosity were calculated
by using themethod offered in Ref. [30], whichwas according to the Ar-
chimedes principle. The total porosity of the scaffolds consisted of
Table 1
Mechanical alloying parameters adopted for milling MCT powder.
Parameter Value
Rotation speed 300 rpm
Ball-powder weight ratio 10:1
Vial and ball material Zirconia
Mass of powder 10 g
Milling time 4 h
Capacity of vial 125 mL
Diameter of the balls 5 and 10 mm
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True density ¼ wt%Mg  ρMg þwt:%Ca  ρCa þwt:%TiO2  ρTiO2 ð1Þ
Total porosity ¼ 1− Wd
ρ Wd−Wsð Þ  100 ð2Þ
where Wd, Ws and ρ are the weight of the sample in air, the weight
of the sample suspended in water, and true density of MCT
(1.987 g/cm3), respectively.
For compression test (Instron 5569, Norwood, MA, USA), cylindrical
scaffolds (10 mm, diameter × 15 mm, height) were prepared and then
compressive strengthwasmeasured using an universal testingmachine
at a crosshead speed of 0.5 mm/min and a load cell of 10 kN at room
temperature.
The antibacterial activity of the MCT-DC scaffolds against Gram-
positive Staphylococcus aureus (S. aureus, ATCC 12600) and Gram-
negative Escherichia coli (E. coli, ATCC 9637) bacteria was examined ac-
cording to the disc diffusion antibiotic sensitivity and liquid medium
microdilution techniques. The antibiotic gentamicin (10 μg/disc,
Oxoid, UK) was employed as the positive control. The inhibition zone
(IZ) around each specimen was assessed to figure out the antibacterial
effect of the MCT-DC scaffolds [31]. An overnight culture of E. coli and
S. aureus was diluted with broth medium to reach the absorbance
value of 0.1–0.2 at 625 nm. Next, the samples (10 mg) were added to
the obtained bacterial suspensions and incubated at 37 °C with a gentle
agitation rate of 100 rpm/min on a shaker platform. At 4 and 24 h time
periods, the absorbance value of all tested solutions was read at 625 nm
using a UV–vis spectrophotometer (Perkin Elmer Lambda 25 UV/VisScheme 1. A schematic of the space holder methoSystems, USA). The bacterial inhibition percentage was determined by
the following equation:
Bacterial inhibition %ð Þ ¼ IC−IS
IC
 100 ð3Þ
where IC is the absorbance value of the control bacterial suspension and
IS is the absorbance value of the bacterial suspension containing differ-
ent samples each time.
For studying the in-vitro DC release of MCT-DC scaffolds, at first the
samples were immersed in phosphate-buffered saline (PBS) and incu-
bated at 37 °C. At each time point, 1 mL of the PBS solution containing
the released DC was collected and restored by fresh PBS solution. The
content of released DC was determined by ultraviolet-visible spectro-
photometry based on the peak from 345 nm by making comparison
with the standard calibration curve.
In order to evaluate bioactivity, MCT-DC scaffolds in the size of
15 mm (diameter) × 10 mm (height) were soaked in the simulated
body fluid (SBF) solution for 7 days. Each scaffold was soaked in
100mLof SBF and kept at 36.5±1 °C for the set period. After immersing
in SBF, the immersed scaffolds were removed, rinsed gentlywith deion-
ized water, and dried at ambient temperature.
The in vitro cytotoxicity of MCT-DC scaffolds was determined by in-
direct 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-zolium-bromide
(MTT, Sigma, Saint Louis, USA) assay based on the extraction method.
Briefly, the culturemediumwas added to the scaffolds (5mg) and incu-
bated at 37 °C for 1 and 2 days. 104 cells/mL were cultured on the 96-
well plates for 24 h. Afterward, the cell medium was refreshed with 1
and 2-day extracts. The medium was removed after another 24 h and
100 μL MTT agent (0.5 mg/mL in PBS) was inoculated into each well
and kept in the incubator for 4 h. After 4 h, 100 μL of DMSO (D2650,
Sigma, Saint Louis, USA) was inserted to the well to dissolve the
formazan crystals. Finally, the absorbance was read at 545 nm by
using an ELISA Reader (Stat Fax-2100, Miami, FL, USA) and normalized
by free scaffolds culture medium as a control group. Nuclear staining
with DAPI (4′, 6-diamidino-2-phenylindole, blue fluorescence in live
cells) was performed in order to examine the MG63 cell proliferation
on the MCT-DC scaffolds under fluorescence microscopy (Carl Zeiss,
Germany).
As for electrochemical measurement, the MCT-TC scaffolds with a
surface area of 1 cm2 were prepared to be measured by PARSTAT 2263d for preparing MCT-DC composite scaffolds.
Fig. 2. FTIR absorption spectra of MCT (a) and MCT-DC composite scaffolds with various
doxycycline concentrations of (b) 1, (c) 5, and (d) 10%.
Fig. 1. XRD pattern (a), and TEMmicrograph (b) of MCT nanopowders after 4 h milling.
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Theywere submerged in a three-electrode cell filledwith Kokubo SBF at
37 °C and with a pH value of 7.44 to meet the requirements of Ref. [28].
Fourier-transform infrared (FTIR; ALPHA-T, Bruker, Ettlingen,
Germany) spectrum was recorded in the spectral range of
4000–450 cm−1 to indicate the surface functional groups of MCT-DC
scaffolds.Microstructures of MCT-DC scaffolds were studied using scan-
ning electron microscopy (SEM, JEOL JSM-6380LA; Jeol Ltd., Japan,
Tokyo) equipped with Oxford energy dispersive X-ray spectrometer
(EDS) analysis with an operating voltage of 20 kV and transmission
electron microscopy (TEM, HT7700 Hitachi, Japan). An X-ray diffrac-
tometer (Siemens D5000, Karlsruhe, Germany) was used to determine
the phase components through Cu-Kα radiation (45 kV, 40 mA) over
the diffraction angles (2θ) of 20–75° at a scanning speed of 4°/min.
The crystallite size was measured using the Williamson–Hall method
[32] based on the following equation:
β
2
cotθ ¼ 0:45λ
SinθD
þ ε ð4Þ
where β is the diffraction peak width at mid-height; λ and D are the
X-ray wavelength and the average crystallite size (nm), respectively;
and ε and θ are the microstrain and the Bragg diffraction angle,
respectively.
3. Results and discussion
The XRD patterns of the MCT synthesis powder after 4 h milling are
presented in Fig. 1a. The characteristic peaks of α-Mg and TiO2 were
found in the XRD patterns of the MCT synthesis powder whereas the
presence of smaller peaks ofMg2Ca and geikielite (MgTiO3) phases indi-
cate the occurrence of mechanically induced self-propagating reactions
(MSR) mechanism based on the following equation: Mg + 1.5TiO2
→MgTiO3 + 0.5Ti. In this context, Sul [33] revealed that the geikielite
(MgTiO3) is biocompatible and osteoconductive; thus, it is suitable for
implant applications. According to the Williamson-Hall equation [32],
theMCT crystallite sizewas in the range of 72 nm. For further confirma-
tion of structural evaluation including crystallite size andmorphology of
the MCT synthesis powder TEM analysis was performed. The TEM
image (Fig. 1b) reveals that the particle size of the powders is in the
range of 30–100 nm. This is in agreement with the crystallite size of
the synthesis powders calculated using the XRD data. In this respect, it
was suggested [34] that the composite with a grain size b100 nm pre-
sented better mechanical and biological properties.
The entire FT-IR spectra (Fig. 2) showed the characteristic peaks
of MCT composite scaffold including the peak in the range of
900–400 cm−1, which is attributed to the Ti\\O\\Ti stretching [35].
The Ti\\O bands were observed at 1395 cm−1, while the band
at 1627 cm−1 was related to the O\\H bands [36]. The band at1083 cm−1 and 3696 cm−1 can be assigned to Mg\\O stretching vibra-
tion. The MCT-DC composite scaffolds presented the characteristic
peaks of DC at 3388, 3000, and 2950 cm−1 which are related to OH,
N\\H, and C\\H stretching vibrations, respectively [37,38]. The bands
at 1745 and 1451 cm−1 are attributed to the amide (N\\H) bending
and aromatic N\\H bending vibrations, respectively. Multiple peaks be-
tween 1400 and 1700 cm−1 are related to aromatic C_O and C_C
stretching [37,38]. Furthermore strong peak at 1557 cm−1 related to
the aromatic N\\H bending. In addition, the bands at 1082 and
846 cm−1 belong to\\CH2 and C\\H bending vibrations, respectively
[39].
The SEM images ofMCT andMCT-DC composite scaffolds containing
1, 5 and 10% doxycycline exhibited (Fig. 3) the formation of porous scaf-
folds consisted of interconnected porosity with pore sizes ranging from
600 to 800 μm. In this respect, it was suggested that the scaffold should
possess an interconnected porous structure besides its porosity size
(N300 μm) for better cell seeding and the growth of tissue [1,2]. It was
also visible that due to the evolution of carbon dioxide gas, macro
pores with pore sizes ranging from 100 to 250 μm were produced
(indicated by arrow). In this respect, Roohani et al. [2] showed that
the presence of micro-pores is crucial since they are required for capil-
lary ingrowth and cell-matrix interactions. As can be seen, by increasing
the concentration of doxycycline, no substantial difference in the pores
size was detected. This indicates that the amount of porosity did not de-
pend on the composition of the scaffolds. It is noteworthy that theMCT-
DC composite scaffolds possess an average total porosity of 65–67%with
a spherical pore morphology which is homogenously distributed. This
implies that carbamide as the spacer agent possesses the particle size
Fig. 3. SEM images of MCT (a) and MCT-DC scaffolds with various doxycycline concentrations of (b) 1, (c) 5, and (d) 10%.
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round-like shapes throughout the fabrication procedure. Some necks
with the size of 100–200 μm between the pores were also observed in
approximately 50% of the pores in the cross section (Fig. 3d), implying
a good level of interconnectivity [40].
The potentiodynamic polarization curves of pure Mg, MCT, and
MCT-DC composite scaffolds in SBF at 37 °C are shown in Fig. 4a. The
corrosion potential (Ecorr) of pure Mg is −1845 ± 13 mVSCE and
shifts to nobler direction (−1733 ± 11 mVSCE) after addition of
Ca and TiO2 to theMg scaffold. The corrosion density (icorr) of MCT scaf-
fold (210.7 ± 10 μA·cm−2) is low compared with the pure Mg scaffold
(40.6 ± 3 μA·cm−2). This is attributed to the existence of a small con-
tent of Ca in the composite scaffold which could stabilize brucite,
Mg(OH)2, and the aforementioned phase (brucite) can act as a protec-
tive layer which slows down the penetration of SBF into the substrate,
hence interrupting the direct interface with the Mg alloy. However,
MCT-DC scaffolds loaded with different concentrations of DC show a
similar Ecorr and icorr, indicating a less significant change observed in
degradation rate with increasing DC from 1 to 10%.
Prior to obtaining the probability to failure of the whole dataset of
MCT-DC composite scaffolds, it was essential to confirm that the addi-
tion of doxycycline had no significant effect on the compressive
strength. According to the preliminary conclusion, the influence ofFig. 4. Potentiodynamic polarization curves of MCT-DC scaffolds (a) and location-related ins
65 vol% carbamide as the spacer.doxycycline on the compressive strength of MCT-DC composite scaffold
was negligible. This is due to the fact that no considerable difference in
the size and shape of the porous MCT scaffolds was found after the in-
corporation of DC into the MCT scaffold. As can be seen in Fig. 4b, the
stress-strain curve of the MCT-DC scaffolds composed of three specific
regions including linear elastic (region 1) which is increased to the
highest compressive strength. Afterward, with increasing the stress,
the entire pores walls were collapsed (region 2), and finally densifica-
tion of the collapsed scaffold occurred via more escalating the stress.
These results are in good agreement with those reported by Ghomi
et al. [30]. The compressive strength of MCT-DC scaffolds consisting of
0, 1, 5 and 10% doxycycline is in the range of 5± 0.1MPa. It was also re-
ported [30] that the scaffolds containing carbamide as the spacer pre-
sented higher compressive strength than those containing sodium
chloride as the spacer as a result of the presence of lower porosity and
pore size.
The in vitro drug release property of MCT-DC scaffolds was evaluat-
ed by dipped of DC loaded scaffolds into the PBS solution (pH= 7.4) at
37 °C. In Fig. 5, both burst and sustained cumulative releasemechanisms
can be seen. Moreover, all samples showed similar release profiles with
slight differences in the amount of released DC. MCT-1DC and MCT-
10DC scaffolds showed the lowest (34.3 ± 0.6%) and highest (37.2 ±
0.3%) burst release during the first 3 h, followed by sustained release1 2 3 
tantaneous changes of the compressive strength of (b) MCT-DC composite scaffold with
Fig. 5. Drug release behavior MCT-DC composite scaffolds with various doxycycline
concentrations.
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ascribed to the existence of more contents of DC. However, DC release
from all scaffolds was completed within 20 h. In addition, the absor-
bance of dissolved scaffolds in HCl solution showed that no sign of DC
was observed, representing complete drug release from the scaffolds
within 20 h. These results demonstrate a favorable release profile that
is suitable for bone infection treatment.
In order to explore the biological efficiency, we have tested antibac-
terial activity of MCT-DC scaffolds against E. coli and S. aureus bacteria.
The localized release of an anti-bacterial agent from the implant, after
the constructive surgery, could prevent the bacteria from invading theFig. 6. Inhibition zones of the MCT and MCT-DC scaffolds against (a) E. coli and (b) S. aureus b
incubation times. Note: (S1): MCT; (S2): MCT-1DC; (S3): MCT-5DC; (S4): MCT-10DC; (Controsurgical site and causing severe complications [24]. Hence, DC-loaded
MCT scaffolds were used in the present study to provide the scaffolds
with antibacterial activity. Fig. 6 shows the zone of inhibition for four
MCT and MCT-DC scaffolds at different bacteria strains (Gram positive
and Gram negative). The mean size of inhibition ring for MCT, MCT-
1DC, MCT-5DC and MCT-10DC scaffolds were 1.12 ± 0.13 mm, 1.45 ±
0.16 mm, 2.51 ± 0.23 mm and 2.95 ± 0.28 mm for E-coli respectively
(Fig. 6a). As can be seenMCT scaffold also presented antibacterial activ-
ity owing to the raise of pH value throughout its degradation in the bac-
terial solution. The killing effect of these MCT-DC scaffolds was
evidenced by the formation of the inhibition zone in the plate. A similar
trend was found for S. aureus (Fig. 6b) since the mean size of inhibition
ring increased with escalating the DC concentration, initiating at 1.18±
0.14mm inMCT, 2.05±0.21mm inMCT-1DC, 2.40±0.22mm inMCT-
5DC, and reaching 3.54±0.32mminMCT-10DC. This indicated that the
antibacterial activity ofMCT-DC in the agar plate against both gramneg-
ative (E. coli) and gram positive (S. aureus) bacteria is more than that of
pure MCT scaffold. As can be observed in the figure, the bacteria were
inhibited to completely grow around the MCT scaffolds containing a
higher concentration of DC, while they were proliferated around the
bare MCT scaffold. This behavior indicates that there was a relationship
between the antibacterial properties of the MCT-DC scaffolds and their
DC concentration. As the DC concentration in the MCT scaffolds in-
creased, the inhibition zone became larger in size. This is due to the
fact that the MCT scaffold with higher DC concentration was able to re-
lease considerably more DC compared to other scaffolds with a lower
DC antibiotic content [25].
Fig. 6c,d also show the percentage of bacterial inhibition of all MCT
and MCT-DC scaffolds at different incubation times. The MCT scaffold
depicts the lowest antimicrobial activity. By contrast, the MCT scaffoldsacteria for 24 h and percentage of bacterial inhibition of the MCT-DC scaffolds at various
l): gentamicin.
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ditionally, the antibacterial activity of the scaffolds increased with the
increase of the content of DC. Of all scaffolds, MCT-10DC scaffold
showed the highest bacterial inhibition of 84.3 ± 2% and 92.5 ± 3%
after 24 h incubation in E. coli and S. aureus suspension, respectively.
However, the lowest bacterial inhibitionwas observed for scaffoldwith-
out DC content. This is attributed to the presence of DC in theMCT scaf-
foldswhich acts as a bacterial barrier to prohibit DNA gyrase essential to
separating bacterial DNA [25,31], hence reducing cell division.
DAPI staining of cell nuclei onMCT-DC scaffolds after 48 h of incuba-
tion in Fig. 7a–d revealed that on the MCT and MCT-DC scaffolds with
low DC content, a large number of cells with spherical shapes were
well spread and attached on the outer parts and the surface of the scaf-
folds, implying suitable cell–scaffold interaction that will lead to
osseointegration of the nano particles. However, the cells on the MCT
scaffold containing high DC content were poorly-spread, indicating
that the scaffolds containing low DC content allow the cells penetrate
and migrate within the scaffolds in a manner similar to native ECM. Cy-
totoxicity of the MCT-DC scaffolds was examined via cell proliferation
assay, as can be seen in Fig. 7e. The MTT cell proliferation assay could
be employed to test the MCT-DC scaffolds associated cytotoxicity. The
concept is that cellular proliferation will decrease considerably in com-
parison to the control sample in case theMCT-DC scaffolds exert any cy-
totoxicity. The results of MTT assay conducted on the MCT andMCT-DC
scaffolds and control specimens after 24 and 48 days of incubation. The
results exhibited that the proliferation of MG63 cells cultured on MCT
scaffold slightly declined with escalating the incubation time toFig. 7. DAPI staining of MG63 cell cultured for 2 days on MCT (a) and MCT-DC scaffolds with
osteoblast cells cultured for 24 and 48 h on MCT-DC scaffolds.48 days due to more release of the DC drug. The MCT scaffold is able
to stimulate the proliferation of osteoblastic-induced bone marrow
cells. However, the MCT-DC scaffolds containing low concentration of
DC depicted a very slight reduction in cell proliferation,whereas this de-
cline is not sufficient to present any cytotoxic effects. It was also visible
that the scaffolds containing high DC content exhibited cytotoxic
behavior. Similarly, it was reported [41] that at low DC concentrations
(1 μg/mL) there is a proanabolic influences over osteoblastic
phenotypic cells, concerning proliferation. While higher DC concentra-
tions (10 μg/mL) have a substantial inhibitory influence in cell growth
and 25 μg/mL leads to absence of cell growth.
Formation of apatite on the scaffolds surface throughout the incuba-
tion in SBF solution ensures the regeneration of bone in the in-vivo con-
ditions [40]. Due to higher cell viability of MCT and MCT-1DC scaffolds
than others, these scaffoldswere chosen for evaluation of apatite forma-
tion ability. Fig. 8 shows the SEM images of the scaffolds after incubation
in the SBF solution for 7 days at 37 °C to determine the bioactivity of the
scaffolds. Different magnifications (Fig. 8a1–4) exhibit that the layer of
apatite has been formed on the scaffold surface owing to the direct con-
tact of SBF. It seems that the apatite is also formed on the inner wall of
the pores as indicated with arrow (Fig. 8a2 and b2), since the
SBF solution has sufficient time to infiltrate inside the scaffold. More-
over, formation of apatite resulted in altering the morphology and size
of the pores in the scaffolds. It is worth noting that due to the growth
of apatite crystals in the inner wall of the pores, the small pores are
filled, hence reducing the pore size which leads to escalating the
strength of scaffolds.various doxycycline concentrations of (b) 1, (c) 5, and (d) 10% and (e) viability of MG63
Fig. 8. SEM images of (a1–4)MCT and (b1–4)MCT-1DC scaffolds after 7 days immersion in SBF solution at differentmagnifications. Note: The red, yellow and green color arrows represent
pores, micro-pores and apatite formation in inner wall of the pores, respectively.
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on the scaffolds surface possesses flower-like nano-flakes with an as-
sembled hierarchical structure. Furthermore, there is no significant
difference in the HA layer formed on MCT and MCT-1DC scaffolds in-
dicating that DC did not obstruct the bioactivity of MCT (Fig. 8b1–4).
The EDS pattern shows the presence of the Mg peak with low inten-
sity and the presence of the calcium, phosphorus, and oxygen with
high intensity. Similar products including Ca, Mg, C, P, and O were
observed in the MCT scaffold containing DC, suggesting that the
product contains HA (Fig. 9a). The atomic ratio of Ca/P of the product
of MCT and MCT-DC scaffolds was about 1.44 and 1.42, respectively,
representing the Ca-deficit hydroxyapatite (HA) formation.Formation of HA represents a high bioactivity and biological perfor-
mance of the scaffolds since it is a vital precondition for the direct
binding of bioactive components to the living bone tissue. The XRD
pattern (Fig. 9b) further confirms the result of EDS analysis since
MCT and MCT-1DC scaffolds presented the strongest HA and peaks,
implying its apatite formation ability in the SBF solution. Broad
Mg(OH)2 diffraction peaks can be related to the poor crystallinity
of these phases. It was reported [42] that the presence of hydroxides
in the corrosion products is a direct evidence of a pitting type of cor-
rosion attack, since hydroxide-based corrosion products can form
deep inside the pits and fall off when the corrosion products covering
the pits disintegrate from the surface.
Fig. 9. EDS spectrum of (a) area A and B, and (b) X-ray diffraction patterns and (c) change of pH value of MCT and MCT-1DC scaffolds after 7 days immersion in SBF solution.
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according to the following equation:
Mgþ 2H2O ¼Mg OHð Þ2 þH2↑ ð5Þ
Afterwards through the formation of brucite (Mg(OH)2) as a protec-
tive layer, the corrosion rate of the scaffold reduce substantially. As a re-
sult of the brucite formation, the CO23−, PO34− and Cl− ions were
attracted to the scaffold surface leading to more accumulation of OH–
ion which is crucial for apatite nucleation. In this context, Li et al. [43]
showed that undissolved brucite layer on the Mg alloy surface was
regarded to accelerate HA nucleation. Subsequently, the nucleation of
a HA layer occurs on the scaffold surface, through the reaction of the
PO34− and Ca2+ ions presence in the SBF. As soon as HA nuclei are
formed on the scaffold surface, they are able to grow through consum-
ing PO34− and Ca2+ ions from SBF.
Fig. 9c exhibited the pH values of the SBF solution immersed the
MCT and MCT-DC scaffolds at various immersion times. It was shown
that when the incubation time was not longer than 24 h, the pH value
elevated rapidly, from7.4 to 9.7, and subsequently the pH value became
stable at about 10.8. It was assumed that the initial escalation of pH
value was attributed to the accumulation of OH ion in the form of
Mg(OH)2 on theMCT scaffold surfaces [24,44,45]. An accelerated pH es-
calation throughout the initial duration of incubation was reported by
numerous in vitro studies [46–48]. The decelerated escalation of pH at
a longer incubation time can be attributed to the deposition of HA on
the surface of MCT scaffold. It was worth mentioning that doxycyclinewas completely released after 20 h and it has less significant effect on al-
tering the pH values of the SBF, henceMCT-DC scaffolds showed similar
pH trend with slight differences in the amount of pH values.4. Conclusions
In this study, novel MCT-xDC (x=1, 5 and 10%) composite scaffolds
were prepared via space holder technique as a novel, cost-effective and
feasible method with interconnected pores and appropriate corrosion
rate and compressive strength. The MCT-DC scaffolds had favorable
pores size (600–800 μm)with total porosity (65–67%). The compressive
strength (CS) and corrosion density (icorr) of MCT scaffold were in the
range of 5 ± 0.1 MPa and 40.6 ± 1 μA·cm−2, respectively. However,
MCT scaffolds loadedwith different concentrations of DC show a similar
CS and icorr. The results of bioactivity study revealed the apatite
formation ability of MCT scaffold loaded with DC. The drug release pro-
files depicted that the burst and sustained drug release were obtained
via DC loading MCT scaffolds and also showed that the drug release
rate increased with increasing the DC concentration. Cytotoxicity tests
showed that the MCT-DC scaffolds with low concentration of DC did
not present toxicity, whereas some toxicity was found in the scaffolds
with high DC concentration. All MCT-DC scaffolds exhibited good bacte-
ricidal properties against S. aureus and E. coli bacteria and their antibac-
terial activities increased with increasing the DC concentration. Thus,
MCT-(1–5%)DC scaffold is an alternative candidate for bone infection
treatment.
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